Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: The EMPA-KIDNEY trial. American Heart Association.
Citace podle Chicago (17th ed.)Preiss, D., W. Herrington, a R. Haynes. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.
Citace podle MLA (9th ed.)Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..